Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Exclusion Criteria

• •Prior allogeneic stem cell transplant.
• •Prior treatment with a PD-1/PD-L1 inhibitor
• •Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment.
• •Current or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab.
• •Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection.
• •History of hypersensitivity to durvalumab or any excipient
• •Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab.
• •Female subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control
• •Male subjects who are not employing an effective method of birth control
• •Uncontrolled current medical illness, including, but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris,unstable cardiac arrhythmia and/or psychiatric illness or other condition that in the opinion of the investigator would limit compliance with study requirements.